Cargando…
Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels
We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916484/ https://www.ncbi.nlm.nih.gov/pubmed/35277828 http://dx.doi.org/10.1007/s11739-022-02955-5 |
_version_ | 1784668307602800640 |
---|---|
author | So, Wonhee Simon, Matthew S. Choi, Justin J. Wang, Tina Z. Williams, Samuel C. Chua, Jason Kubin, Christine J. |
author_facet | So, Wonhee Simon, Matthew S. Choi, Justin J. Wang, Tina Z. Williams, Samuel C. Chua, Jason Kubin, Christine J. |
author_sort | So, Wonhee |
collection | PubMed |
description | We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March–May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, ‘do not resuscitate ± do not intubate’ status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-02955-5. |
format | Online Article Text |
id | pubmed-8916484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-89164842022-03-14 Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels So, Wonhee Simon, Matthew S. Choi, Justin J. Wang, Tina Z. Williams, Samuel C. Chua, Jason Kubin, Christine J. Intern Emerg Med Im - Original We examined the characteristics of pro-calcitonin (PCT) in hospitalized COVID-19 patients (cohort 1) and clinical outcomes of antibiotic use stratified by PCT in non-critically ill patients without bacterial co-infection (cohort 2). Retrospective reviews were performed in adult, hospitalized COVID-19 patients during March–May 2020. For cohort 1, we excluded hospital transfers, renal disease and extra-pulmonary infection without isolated pathogen(s). For cohort 2, we further excluded microbiologically confirmed infection, ‘do not resuscitate ± do not intubate’ status, and intensive care unit (ICU). For cohort 1, PCT was compared between absent/low-suspicion and proven bacterial co-infections. Factors associated with elevated PCT and sensitivity/specificity/PPV/NPV of PCT cutoffs for identifying bacterial co-infections were explored. For cohort 2, clinical outcomes including mechanical ventilation within 5 days (MV5) were compared between the antibiotic and non-antibiotic groups stratified by PCT ≥ 0.25 µg/L. Nine hundred and twenty four non-ICU and 103 ICU patients were included (cohort 1). The median PCT was higher in proven vs. absent/low-suspicion of bacterial co-infection. Elevated PCT was significantly associated with proven bacterial co-infection, ICU status and oxygen requirement. For PCT ≥ 0.25 µg/L, sensitivity/specificity/PPV/NPV were 69/65/6.5/98% (non-ICU) and 75/33/8.6/94% (ICU). For cohort 2, 756/1305 (58%) patients were included. Baseline characteristics were balanced between the antibiotic and non-antibiotic groups except PCT ≥ 0.25 µg/L (antibiotic:non-antibiotic = 59%:24%) and tocilizumab use (antibiotic:non-antibiotic = 5%:2%). 23% (PCT < 0.25 µg/L) and 58% (PCT ≥ 0.25 µg/L) received antibiotics. Antibiotic group had significantly higher rates of MV5. COVID-19 severity inferred from ICU status and oxygen requirement as well as the presence of bacterial co-infections were associated with elevated PCT. PCT showed poor PPV and high NPV for proven bacterial co-infections. The use of antibiotics did not show improved clinical outcomes in COVID-19 patients with PCT ≥ 0.25 µg/L outside of ICU when bacterial co-infections are of low suspicion. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11739-022-02955-5. Springer International Publishing 2022-03-11 2022 /pmc/articles/PMC8916484/ /pubmed/35277828 http://dx.doi.org/10.1007/s11739-022-02955-5 Text en © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Im - Original So, Wonhee Simon, Matthew S. Choi, Justin J. Wang, Tina Z. Williams, Samuel C. Chua, Jason Kubin, Christine J. Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title | Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title_full | Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title_fullStr | Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title_full_unstemmed | Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title_short | Characteristics of procalcitonin in hospitalized COVID-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
title_sort | characteristics of procalcitonin in hospitalized covid-19 patients and clinical outcomes of antibiotic use stratified by procalcitonin levels |
topic | Im - Original |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916484/ https://www.ncbi.nlm.nih.gov/pubmed/35277828 http://dx.doi.org/10.1007/s11739-022-02955-5 |
work_keys_str_mv | AT sowonhee characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT simonmatthews characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT choijustinj characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT wangtinaz characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT williamssamuelc characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT chuajason characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels AT kubinchristinej characteristicsofprocalcitonininhospitalizedcovid19patientsandclinicaloutcomesofantibioticusestratifiedbyprocalcitoninlevels |